ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
P/E ratio for ShockWave Medical, Inc. (SWAV)
P/E ratio as of 2023: 47.49
According to ShockWave Medical, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 47.49. At the end of 2022 the company had a P/E ratio of 34.17.
P/E ratio history for ShockWave Medical, Inc. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 47.49 |
| 2022 | 34.17 |
| 2021 | -685.10 |
| 2020 | -52.24 |
| 2019 | -20.54 |
| 2018 | -19.97 |
| 2017 | -19.45 |